Psy16 - Health Outcome Improvements in Spinal Muscular Atrophy Type 1 Patients With Avxs-101 Gene Replacement Therapy

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2593
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy18 - Rapid Improvements in Motor Function in Spinal Muscular Atrophy Type 1 Following Avxs-101 Gene Replacement Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

014 AVXS-101 Gene-Replacement Therapy (GRT) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

P.065 AVXS-101 Gene-Replacement Therapy (GRT)) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Canadian Journal of Neurological Sciences
MedicineNeurology
2019English

066 Avxs-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

Spinal Muscular Atrophy Type 1

Pediatric Critical Care Medicine
Child HealthCritical CarePediatricsPerinatologyIntensive Care Medicine
2012English

Gene Therapy in Mouse Models of Spinal Muscular Atrophy :||Using SMN Gene Replacement to Address Biological Questions

English

Respiratory Management of the Infant With Type 1 Spinal Muscular Atrophy

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2005English

Spinal Muscular Atrophy With Respiratory Distress Type 1—A Child With Atypical Presentation

Child Neurology Open
2018English

Pnd41 - Healthcare Costs of Patients With Spinal Muscular Atrophy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy